Welcome to CDC Stacks | The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children’s Hospital through the PCV7 Era - 33322 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children’s Hospital through the PCV7 Era
Filetype[PDF - 425.06 KB]


Details:
  • Pubmed ID:
    22330164
  • Pubmed Central ID:
    PMC3299810
  • Funding:
    1K23-AI079401-01A1/AI/NIAID NIH HHS/United States
    K-24 HD047249-01A1/HD/NICHD NIH HHS/United States
    K23 AI079401/AI/NIAID NIH HHS/United States
    K24 HD047249/HD/NICHD NIH HHS/United States
    K24 HD047249-01A1/HD/NICHD NIH HHS/United States
    U01 AI074419-01/AI/NIAID NIH HHS/United States
    U01A1082482/PHS HHS/United States
    U01AI082184-01/AI/NIAID NIH HHS/United States
    U18-IP000303-01/IP/NCIRD CDC HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Background

    In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use among U.S. children. Many sites have since reported changes in invasive pneumococcal disease (IPD). We recognized an opportunity to describe the changes in epidemiology, clinical syndromes and serotype distribution over a 14 year period including 4 years before vaccine introduction and spanning the entire PCV7 era.

    Methods

    Cases were defined as children <18 years of age who were cared for at Primary Children’s Medical Center for culture-confirmed IPD. We defined the pre-vaccine period as the timeframe spanning 1997–2000 and the post-vaccine period from 2001–2010. Demographics, clinical data, and outcomes were collected through electronic query and chart review. S. pneumoniae serotyping was performed using the capsular swelling method.

    Results

    The median age of children with IPD increased from 19 months during the pre-vaccine period to 27 months during post-vaccine period (P = 0.02) with a larger proportion of IPD among children older than 5 years. The proportion of IPD associated with pneumonia increased substantially from 29% to 50% (P < 0.001). This increase was primarily attributable to an increase in complicated pneumonia (17% to 33%; P < 0.001). Non-vaccine serotypes 7F, 19A, 22F and 3 emerged as the dominant serotypes in the post-vaccine period. Of S. pneumoniae isolates collected from children <5 years of age, for which vaccine is recommended, 67% of IPD was due to serotypes in PCV13 during 2005–2010.

    Conclusions

    After PCV7 was introduced, significant changes in IPD were noted. One third of IPD occurred in children older than 5 years, who were outside the age group for which PCV is recommended. Continued surveillance is warranted to identify further evolution of the epidemiology, clinical syndromes, and serotype distribution of S. pneumoniae following PCV13 licensure.